Diffuse panbronchiolitis is an intractable disease of adult patients, often elderly, which involves infiltration of plasma cells and lymphocytes with inflammatory hypertrophy of the walls of the respiratory bronchioles.' It is predominantly seen in men. The main sites of the chronic inflammation are the bronchiolar and centrilobular regions, and the main symptoms are dyspnoea, cough, and expectoration. The disease was first described in Japan in 1969 and subsequently in Korea and China, and a few cases have been reported outside Asia -notably in Asian emigrants -probably too few as the disease is virtually unknown by physicians in the western world. However, by 1983 more than 1000 cases of probable diffuse panbronchiolitis and 82 histologically confirmed cases had been reported.2
In this issue of Thorax two studies are published on patients with diffuse panbronchiolitis.34 Koyama and colleagues' have examined the bronchial responsiveness to methacholine in patients with diffuse panbronchiolitis and a group with chronic obstructive pulmonary disease, and also the response to bronchodilators in two larger groups. They found substantial differences in both the methacholine and the bronchodilator response between the two diseases, with much lesser responses being found in the patients with diffuse panbronchiolitis. They suggest that the airflow restriction in bronchiolitis is much more fixed than in chronic obstructive pulmonary disease due to irreversible structural changes within the bronchioles. Tamaoki and colleagues4 report the effect of long term inhalation of oxitropium bromide in patients with diffuse panbronchiolitis and a group with chronic bronchitis. After five weeks they reported improved airway flow and decreased sputum quantity, but no change in sputum bacteriology.
The aetiology of the disease, however, is not yet clear. Haemophilus influenzae infections occur repeatedly or continuously over a long course and, during this time, the respiratory bronchioles become obstructed and the nearby airway bronchioles become dilated. With these morphological changes superinfection with Pseudomonas aeruginosa occurs and the disease becomes intractable.' Polymorphonuclear leucocytes become more abundant and free polymorphonuclear leucocyte elastase is present in bronchial fluid and participates in the tissue damage."7 Antibodies in serum and sputum against Ps aeruginosa are present.8 The chronic Ps aeruginosa infection is caused by mucoid strains of these bacteria growing as a biofilm which is virtually impossible to eradicate by means of antibiotics. 9 In 1987 the Research Project team of the Ministry of Health and Welfare for Specific Diseases in Japan found that the 10 year survival rate was 12-4% in cases infected with Ps aeruginosa and 73 1 % in cases without Ps aeruginosa infection.' Chronic suppressive treatment with long term daily erythromycin is reported to reduce significantly the symptoms and inflammatory parameters and to increase the 10 year survival to more than 90%.' Similar results have been obtained with the new macrolides such as clarithromycin and with fluoroquinolones. The efficacy of macrolides, in spite of their lack of bacteriostatic or bacteriocidal effect against Ps aqruginosa,'0 has been studied in vitro and in animal models and it seems that it results from a sub-MIC effect which inhibits the production of proteins such as the exoproteases of Ps aeruginosa and from interference with the biofilm matrix.9" Such effects are not routinely investigated in the clinical microbiology laboratory, and in this respect the ordinary reports of sensitivity testing are of no help to clinicians. ' 16 In older children and adult patients these bacteria may still play a part, but the major pathogen is Ps aeruginosa. 16 The chronic Ps aeruginosa infection is caused by mucoid strains of these bacteria growing as a biofilm which is virtually impossible to eradicate with antibiotics.'6 The most remarkable host response to the infection is the pronounced antibody response which continues to increase over many years, and which is correlated with poor prognosis. '7 The correlation between the antibody response and poor prognosis is due to immune complex mediated chronic inflammation in the lungs of patients with cystic fibrosis.'7 18 The inflammatory reaction is dominated by polymorphonuclear leucocytes and released leucocyte proteases, myeloperoxidase and oxygen radicals are the main mechanisms of lung tissue damage; in this process the high levels of cytokines (IL-1, IL-6, TNF, and IRAP) in sputum is probably also important. 
